Ekso Bionics (NASDAQ:EKSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note published on Wednesday morning. The firm issued a hold rating on the stock.

Other analysts have also recently issued research reports about the stock. Lake Street Capital started coverage on shares of Ekso Bionics in a research note on Monday, June 24th. They issued a buy rating and a $2.50 price objective for the company. HC Wainwright reiterated a buy rating and issued a $10.00 price target on shares of Ekso Bionics in a research report on Tuesday, July 30th.

Ekso Bionics Price Performance

Ekso Bionics stock opened at $1.04 on Wednesday. The company has a market capitalization of $18.90 million, a price-to-earnings ratio of -1.07 and a beta of 1.45. The stock’s 50 day moving average is $1.10 and its 200-day moving average is $1.20. The company has a current ratio of 2.42, a quick ratio of 1.77 and a debt-to-equity ratio of 0.36. Ekso Bionics has a 12 month low of $0.68 and a 12 month high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings data on Monday, July 29th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Ekso Bionics had a negative net margin of 68.41% and a negative return on equity of 92.08%. The firm had revenue of $4.95 million during the quarter, compared to analyst estimates of $5.34 million. During the same period in the prior year, the company earned ($0.31) earnings per share. Equities research analysts expect that Ekso Bionics will post -0.42 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC raised its position in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 596,050 shares of the company’s stock after buying an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned about 3.28% of Ekso Bionics worth $811,000 at the end of the most recent quarter. 6.42% of the stock is currently owned by hedge funds and other institutional investors.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.